Want to see HNGE full AI Analyst Report?
HNGE Stock Chart & Stats
$43.32
-$1.41(-3.71%)
At close: 4:00 PM EDT
$43.32
-$1.41(-3.71%)
Day’s Range― - ―
52-Week Range$30.08 - $84.62
Previous Close$36.79
Volume525.07K
Average Volume (3M)1.78M
Market Cap
$6.42B
Enterprise Value$5.01B
Total Cash (Recent Filing)$317.31M
Total Debt (Recent Filing)$6.97M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 04, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.58
Shares Outstanding54,655,926
10 Day Avg. Volume2,103,470
30 Day Avg. Volume1,783,940
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)9.72
Price to Sales (P/S)6.26
P/FCF Ratio21.54
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue7.75
Enterprise Value/Gross Profit9.58
Enterprise Value/Ebitda-9.59
Forecast
1Y Price Target
$77.00Price Target Upside77.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)2.57
Revenue Forecast (FY)$819.72M
Bulls Say, Bears Say
Bulls Say
Material Improvement In Cash GenerationA sustained swing to strong operating and free cash flow provides durable internal financing for growth initiatives, reduces dependence on external capital, and supports capital returns and strategic device investment. Strong FCF underpins resilience even if GAAP earnings remain volatile.
Conservative, Low‑leverage Balance SheetMinimal debt and growing assets give the company financial flexibility to invest in product rollout, absorb reimbursement or payment timing shocks, and pursue M&A or buybacks. Low leverage materially lowers solvency risk and preserves capacity for multi‑year strategic initiatives.
Product Expansion And Commercial TractionFDA clearance plus rapid adoption broadens the addressable market beyond MSK into migraine, diversifying revenue streams. Expanded provider network and distribution through PBMs and major plans deepen market penetration and increase customer stickiness and long‑term pricing leverage.
Bears Say
Severe Earnings Volatility And Large 2025 Accounting LossA dramatic swing to a very large net loss raises earnings‑quality concerns: substantial non‑cash charges, one‑time items, or a cost ramp cloud the view on normalized margins. This complicates multi‑period forecasting, capital allocation, and investors' ability to rely on reported earnings sustainability.
Rising Device Distribution Creates COGS PressureScaling physical device distribution entrenches recurring COGS exposure; unless unit device costs fall or yield per life meaningfully rises, broader device adoption can compress gross margins and slow margin expansion, making operational leverage harder to sustain over multiple years.
Portion Of Book Remains On Legacy Subscription PricingWith ~20% of lives on legacy subscription terms, meaningful ARPU and yield upside depends on slow contract migrations. The phased transition limits near‑term revenue per life improvements and delays realization of the platform's full pricing economics and margin benefits.
Hinge Health, Inc. Class A News
HNGE FAQ
What was Hinge Health, Inc. Class A’s price range in the past 12 months?
Hinge Health, Inc. Class A lowest stock price was $30.08 and its highest was $84.62 in the past 12 months.
What is Hinge Health, Inc. Class A’s market cap?
Hinge Health, Inc. Class A’s market cap is $6.42B.
When is Hinge Health, Inc. Class A’s upcoming earnings report date?
Hinge Health, Inc. Class A’s upcoming earnings report date is Aug 04, 2026 which is in 34 days.
How were Hinge Health, Inc. Class A’s earnings last quarter?
Hinge Health, Inc. Class A released its earnings results on May 05, 2026. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.397 by $0.053.
Is Hinge Health, Inc. Class A overvalued?
According to Wall Street analysts Hinge Health, Inc. Class A’s price is currently Undervalued.
Does Hinge Health, Inc. Class A pay dividends?
Hinge Health, Inc. Class A does not currently pay dividends.
What is Hinge Health, Inc. Class A’s EPS estimate?
Hinge Health, Inc. Class A’s EPS estimate is 0.61.
How many shares outstanding does Hinge Health, Inc. Class A have?
Hinge Health, Inc. Class A has 54,655,926 shares outstanding.
What happened to Hinge Health, Inc. Class A’s price movement after its last earnings report?
Hinge Health, Inc. Class A reported an EPS of $0.45 in its last earnings report, beating expectations of $0.397. Following the earnings report the stock price went up 10.231%.
Which hedge fund is a major shareholder of Hinge Health, Inc. Class A?
Currently, no hedge funds are holding shares in HNGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hinge Health, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.00 (77.75% Upside)
$77.00 (77.75% Upside)
Blogger Sentiment
Bullish
HNGE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $174.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.18%
12-Months-Change
Fundamentals
Return on Equity
-138.70%
Trailing 12-Months
Asset Growth
2.28%
Trailing 12-Months
Company Description
Hinge Health, Inc. Class A
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of needs, including general musculoskeletal care, acute injuries, persistent chronic pain, and post-operative rehabilitation. Furthermore, the company provides essential administrative and operational assistance.
HNGE Company Deck
HNGE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: a material revenue beat, double-digit growth in billings, substantial margin expansion, strong free cash flow, raised full-year guidance, rapid client uptake of the new migraine program following FDA clearance, and expanding commercial traction (including SMB and Hinge Select). Headwinds and risks include limited near-term revenue from migraine (meaningful benefit expected in 2027), concentration of new bookings in the back half of the year, continued device-related cost pressures as Enso distribution scales, and a deliberate decision to forgo the CMS ACCESS program. Overall, the positives (robust growth, margin expansion, guidance raise, product and commercial wins) substantially outweigh the near-term lowlights and risks.View all HNGE earnings summariesHNGE Stock 12 Month Forecast
Average Price Target
$77.00
▲(77.75% Upside)
Technical Analysis
Ownership Overview
8.48% Insiders
18.38% Mutual Funds
67.21% Other Institutional Investors
0.02% Public Companies and
Individual Investors